Molecular determinants for competitive inhibition of α4β2 nicotinic acetylcholine receptors

Molecular Pharmacology

Volumn 78, Issue 3, 2010, Pages 366-375

  Iturriaga Vásquez, Patricio ^a   Carbone, Annalisa ^b   García Beltrán, Olimpo ^a   Livingstone, Phil D ^c   Biggin, Philip C ^d   Cassels, Bruce K ^a   Wonnacott, Susan ^c   Zapata Torres, Gerald ^a   Bermudez, Isabel ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b OXFORD BROOKES UNIVERSITY   (United Kingdom)

^c University of Bath   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; DIHYDRO BETA ERYTHROIDINE; ERYTHRINA ALKALOID; NICOTINIC RECEPTOR ALPHA4BETA2; ALKALOID; AZOCINE DERIVATIVE; BETA-ERYTHROIDINE; CYTISINE; ERYSODINE; NICOTINIC RECEPTOR; QUINOLIZINE DERIVATIVE;

ARTICLE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; FEMALE; METABOLISM; PHYSIOLOGY; XENOPUS LAEVIS;

ALKALOIDS; ANIMALS; AZOCINES; DIHYDRO-BETA-ERYTHROIDINE; FEMALE; QUINOLIZINES; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 77956246788     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.065490     Document Type: Article

References (36)

1. Arneric SP, Holladay M, and Williams M (2007) Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol 74: 1092-1101.
2. Bafna PA, Jha A, and Auerbach A (2009) Aromatic residues εTrp-55 and δTrp-57 and the activation of acetylcholine receptor channels. J Biol Chem 284:8582-8588.
3. Beene DL, Brandt GS, Zhong W, Zacharias NM, Lester HA, and Dougherty DA (2002) Cation-π interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic aceylcholine receptors: the anomalous binding properties of nicotine. Biochemistry 41:10262-10269.
4. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, and Sixma TK (2001) Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411:269-276.
5. Case DA, Darden TA, Cheatham TE III, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM, Pearlman DA, Crowley M, et al. (2006) AMBER 9, University of California, San Francisco.
6. Cassels BK, Bermú dez I, Dajas F, Abin-Carriquiry JA, and Wonnacott S (2005) From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. Drug Discovery Today 10:1657-1665.
7. Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, and Johnson EC (1997) Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors hα2β2, hα2β4, hα3β2, hα3β4, hα4β2, hα4β4 and hα7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 280:346-356.
8. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Decker MW, Anderson DJ, Brioni JD, Donnelly-Roberts DL, Kang CH, O'Neill AB, Piattoni-Kaplan M, Swanson S, and Sullivan JP. J (1995) Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors. Eur J Pharmacol 280: 79-89.
10. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, and Lukas RJ (2003) Characterization of human α4β2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol 64:1283-1294.
11. Galzi JL, Bertrand D, Devillers-Thiéry A, Revah F, Bertrand S, and Changeux JP (1991) Functional significance of aromatic amino acids from three peptide loops of the α7 neuronal nicotinic receptor site investigated by site-directed mutagenesis. FEBS Lett 294:198-202.
12. Grutter T, Prado de Carvalho L, Le Novère N, Corringer PJ, Edelstein S, and Changeux JP (2003) An H-bond between two residues from different loops of the acetylcholine binding site contributes to the activation mechanism in nicotinic receptors. EMBO J 22:1990-2003.
13. Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, and Bourne Y (2005) Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. EMBO J 24:3635-3646.
14. Harvey SC and Luetje CW (1996) Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor β subunits. J Neurosci 16:3798-3806.
15. Horenstein NA, McCormack TJ, Stokes C, Ren K, and Papke RL (2007) Reversal of agonist selectivity by mutations of conserved amino acids in the binding site of nicotinic acetylcholine receptors. J Biol Chem 282:5899-5909.
16. Houlihan LM, Slater Y, Guerra DL, Peng JH, Kuo YP, Lukas RJ, Cassels BK, and Bermudez I (2001) Activity of cytisine and its brominated isosteres on recombinant human α7, α4β2 and α4β4 nicotinic acetylcholine receptors. J Neurochem 78: 1029-1043.
17. Kuryatov A, Onksen J, and Lindstrom J (2008) Roles of accessory subunits in α4β2* nicotinic receptors. Mol Pharmacol 74:132-143.
18. Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J, and Bencherif M (2008) TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic acetylcholine receptor modulator with antidepressant activity. CNS Neurosci Ther 14: 266-277.
19. Livingstone PD, Srinivasan J, Kew JN, Dawson LA, Gotti C, Moretti M, Shoaib M, and Wonnacott S (2009) α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci 29:539-550.
20. Marks MJ, Whiteaker P, Calcaterra J, Stitzel JA, Bullock AE, Grady SR, Picciotto MR, Changeux JP, and Collins AC (1999) Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the β2 subunit. J Pharmacol Exp Ther 289:1090-1103.
21. 2+ potentiation. J Neurosci 28:6884-6894.
22. Moroni M, Zwart R, Sher E, Cassels BK, and Bermudez I (2006) α4β2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine. Mol Pharmacol 70:755-768.
23. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew R, and Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19:1639-1662.
24. Mukhtasimova N, Free C, and Sine SM (2005) Initial coupling of binding to gating mediated by conserved residues in muscle nicotinic receptor. J Gen Physiol 126: 23-39.
25. Mukhtasimova N, Lee WY, Wang HL, and Sine SM (2009) Detection and trapping of intermediate states priming nicotinic receptor channel opening. Nature 459:451-454.
26. Papke RL, Dwoskin LP, Crooks PA, Zheng G, Zhang Z, McIntosh JM, and Stokes C (2008) Extending the analysis of nicotinic receptor antagonists with the study of α6 nicotinic receptor subunit chimeras. Neuropharmacology 54:1189-1200.
27. Peng JH, Fryer JD, Hurst RS, Schroeder KM, George AA, Morrissy S, Groppi VE, Leonard SS, and Lukas RJ (2005) High-affinity epibatidine binding of functional, human α7 nicotinic acetylcholine receptors stably and heterologously expressed de novo in SH-EP1 cells. J Pharmacol Exp Ther 313:24-35.
28. 3H]dopamine release from rat cortex and striatum. Neuropharmacology 39:2673-2680.
29. Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815.
30. Taly A, Corringer PJ, Guedin D, Lestage P, and Changeux JP (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8:733-750.
31. Thompson JD, Higgins DG, and Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673-4680.
32. Tønder JE and Olesen PH (2001) Agonists at the α4β2 nicotinic acetylcholine receptors: structure-activity relationships and molecular modelling. Curr Med Chem 8:651-674.
33. Unwin N (2005) Refined structure of the nicotinic acetylcholine receptor at 4Å resolution. J Mol Biol 346:967-989.
34. Williams DK, Stokes C, Horenstein NA, and Papke RL (2009) Differential regulation of receptor activation and agonist selectivity by highly conserved tryptophans in the nicotinic acetylcholine receptor binding site. J Pharmacol Exp Ther 330:40-53.
35. Xiu X, Puskar NL, Shanata JA, Lester HA, and Dougherty DA (2009) Nicotine binding to brain receptors requires a strong cation-π interaction. Nature 458:534-537.
36. Zhong W, Gallivan JP, Zhang Y, Li L, Lester HA, and Dougherty DA (1998) From ab initio quantum mechanics to molecular neurobiology: a cation-π binding site in the nicotinic receptor. Proc Natl Acad Sci USA 95:12088-12093.